Event-Driven Stocks

Sigilon Therapeutics, Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs1 good3 warning1 severedetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20
Revenue$12.9M$9.6M$13.4M
Operating income−$43.7M−$75.6M−$52.6M
Net income−$43.6M−$77.3M−$54.6M
Total assets$87.3M$144.4M$225.1M
Total liabilities$48.1M$67.2M$78.9M
Equity$39.1M$77.2M$146.2M
EPS (diluted)$-1.34$-2.43$-7.55
Shares out.32.4M32.4M31.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
−337.3%
Net margin
−336.5%
Return on equity
−111.3%
Return on assets
−49.9%
Return on capital (ROCE)
−77.6%
Liabilities / assets
55.2%
Debt / equity
1.23×
Book value / share
$1.21
Revenue growth (YoY)
34.8%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Altman Z″ (distress)
-8.84distress
Accruals / assets
9.1%moderate
Piotroski F-Score
3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
55
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

1 severe3 warning1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
1 acquisitions5 disposals1 open-market buy(s)net +1.0M shares · last 6
InsiderDateTypeSharesPrice
Flagship Ventures Fund V General Partner Llc10% ownerAug 11, 2023U683,760$14.92
Eli Lilly &Amp; Co10% ownerAug 11, 2023Buy1.7M$14.92
Cox JohnDirectorAug 11, 2023D341
Kowalsky Matthew PaulOfficer — CHIEF OF STAFF AND CLOAug 11, 2023D1,925
Yuan Qing SarahOfficer — CTOOAug 11, 2023D2,884
Vivaldi Coelho RogerioOfficer — PRESIDENT AND CEOAug 11, 2023D12,169

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.